This review assessed the effectiveness of peri-operative beta-blocker treatment in patients undergoing noncardiac surgery. The authors concluded that the evidence for a reduction in cardiovascular events is encouraging but inconclusive. These conclusions are likely to be reliable, and are pending the results of further trials in this area.
Assessment of study quality
The validity of the primary studies appears to have been assessed according to: the methods of randomisation; whether the trial was stopped early; the blinding of patients, health care providers, data collectors and outcome assessors; and the completeness of follow-up. Two reviewers independently assessed study quality. Any disagreements were resolved through discussion and consensus.
Data extraction
Two reviewers independently extracted the data. Any disagreements were resolved through discussion and consensus. Data were abstracted on the relative risks (RRs) of the outcomes for patients receiving peri-operative beta-blocker treatment compared with those receiving placebo or standard care. The 95% and 99% confidence intervals (CIs) were then calculated for each RR. All data were extracted in an intention-to-treat format.
Methods of synthesis
How were the studies combined?
The studies were combined in a meta-analysis using the random-effects model of DerSimonian and Laird. Further statistical techniques were used to assess the sample size required for the meta-analysis to be both reliable and conclusive. Publication bias was not assessed.
How were differences between studies investigated?
Heterogeneity was assessed statistically using the I-squared test. I-squared was considered to be low if its value was less than 25%, and high if above 75%. The potential sources of heterogeneity that were explored included trial validity, treatment interventions and the duration of follow-up.
Results of the review
Twenty-two RCTs involving 2,437 participants were included.
A moderate number of major peri-operative cardiovascular events (18 cardiovascular deaths, 58 nonfatal MIs and 7 nonfatal cardiac arrests) were observed in the trials. Treatment with peri-operative beta-blockers was not associated with any significant treatment benefit on any of the individual outcomes of total mortality, cardiovascular mortality, nonfatal MI, nonfatal cardiac arrest, nonfatal stroke or congestive heart failure. For the composite outcome measure of major peri-operative cardiovascular event (cardiovascular death, nonfatal MI, or nonfatal cardiac arrest), a statistically significant treatment benefit in favour of treatment with beta-blockers was observed in comparison with placebo or usual care (RR 0.44, 95% CI: 0.20, 0.97). Moderate heterogeneity was observed across the trials, with I-squared equal to 42%. Treatment with beta-blockers was also associated with a significant increase in the risk of experiencing bradycardia needing treatment (RR 2.27, 95% CI: 1.53, 3.36) and hypotension needing treatment (RR 1.27, 95% CI: 1.04, 1.56). Both of these analyses were associated with low levels of heterogeneity: 3% and 6% for bradycardia needing treatment and hypotension needing treatment, respectively.
A Lan DeMets sequential monitoring boundary was conducted for the meta-analysis. The results indicated that the optimal information size needed to reliably detect a plausible treatment effect for the composite outcome of major perioperative cardiovascular events was 6,124 participants, whereas the actual number of participants included in the metaanalysis was 1,152.
